Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 5945Pancreatic Neoplasms 3561Carcinoma, Hepatocellular 3271Stomach Neoplasms 3056Colonic Neoplasms 2327Rectal Neoplasms 2191Esophageal Neoplasms 1800Liver Neoplasms 1246Neoplasms 1181Breast Neoplasms 1064Neoplasm Metastasis 870Carcinoma, Non-Small-Cell Lung 792Lung Neoplasms 744Cholangiocarcinoma 743Gastrointestinal Neoplasms 662Ovarian Neoplasms 630Esophageal Squamous Cell Carcinoma 584Prostatic Neoplasms 485Melanoma 457Biliary Tract Neoplasms 441Head and Neck Neoplasms 376Uterine Cervical Neoplasms 344Carcinoma, Renal Cell 329Gastrointestinal Stromal Tumors 326Adenocarcinoma Of Esophagus 315Sarcoma 303Barrett Esophagus 300Anus Neoplasms 284Gallbladder Neoplasms 283Endometrial Neoplasms 281

Interventions

trifluridine tipiracil drug combination 1tipiracil 1pembrolizumab 1Trifluridine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastric and Gastroesophageal Junction Adenocarcinoma × Gastrointestinal × Clear all
NCT05508737 2025-07-11

Pembrolizumab and Trifluridine/Tipiracil With Previously Treated Advanced Gastric Cancer

Yonsei University

Phase 1/2 Active not recruiting
75 enrolled
Gastrointestinal

Gastric and Gastroesophageal Junction Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡